Literature DB >> 24635136

Clinical course of untreated pediatric brainstem cavernous malformations: hemorrhage risk and functional recovery.

Da Li1, Shu-Yu Hao, Jie Tang, Xin-Ru Xiao, Gui-Jun Jia, Zhen Wu, Li-Wei Zhang, Jun-Ting Zhang.   

Abstract

OBJECT: The aim of this study was to investigate the clinical appearance of untreated pediatric brainstem cavernous malformations (CMs) and to identify the hemorrhage risks and functional outcomes.
METHODS: All pediatric patients with a diagnosis of brainstem CM between 1985 and 2012 were registered. The clinical chart and radiographs were recorded, and follow-up evaluations were obtained prospectively.
RESULTS: A total of 85 patients (69.4% male) were included with a mean age of 12.7 years. Sixty-seven patients (78.8%) had prior hemorrhage, and 6 patients (7.1%) were asymptomatic. There were 15 midbrain lesions, 53 pons lesions, and 17 medulla lesions. The mean lesion size was 1.9 cm. During a total of 401.6 patient-years of follow-up, 47 hemorrhages occurred in 37 patients, and the annual hemorrhage rate was 11.7% per patient-year. The mean hemorrhage interval was 47.8 months. The hemorrhage risk declined over time, especially after the first 2 years. Both a lesion size ≥ 2 cm (hazard ratio [HR] 2.122, p = 0.037) and the presence of perilesional edema (HR 2.192, p = 0.039) predicted future hemorrhage and were associated with a high annual hemorrhage rate. The hemorrhage-free survival at 6 months was 85.7%, and at 1, 5, 10, and 15 years was 71.5%, 49.4%, 27.5%, and 13.7%, respectively. At the most recent functional evaluation, 33 patients (38.8%) had improved, 32 (37.6%) had stabilized, and 20 (23.5%) had worsened, without any deaths. Twenty-two patients (25.9%) obtained a full recovery. Prospective hemorrhage (HR 0.191, p = 0.003) was the adverse predictor for full recovery. Full recovery primarily occurred within the first 12 months, after which the chance of full recovery decreased. The cumulative percentage of complete recovery at 6 months was 32.7%, and at 1, 3, and 5 years was 40.8%, 43.6%, and 49.2%, respectively.
CONCLUSIONS: In this study the hemorrhage rate was relatively high in pediatric brainstem CMs, although the functional outcome was acceptable. The decline in hemorrhage risk and the identified adverse predictors in this study were helpful for clinicians and patients when deciding on treatment. Referral bias and the insufficient follow-up period of the study were highlighted as limitations.

Entities:  

Mesh:

Year:  2014        PMID: 24635136     DOI: 10.3171/2014.2.PEDS13487

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  8 in total

Review 1.  Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies.

Authors:  Shervin Taslimi; Amirhossein Modabbernia; Sepideh Amin-Hanjani; Fred G Barker; R Loch Macdonald
Journal:  Neurology       Date:  2016-04-22       Impact factor: 9.910

2.  Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease.

Authors:  Romuald Girard; Omaditya Khanna; Robert Shenkar; Lingjiao Zhang; Meijing Wu; Michael Jesselson; Hussein A Zeineddine; Anupriya Gangal; Maged D Fam; Christopher C Gibson; Kevin J Whitehead; Dean Y Li; James K Liao; Changbin Shi; Issam A Awad
Journal:  Biomark Med       Date:  2016-02-09       Impact factor: 2.851

Review 3.  Presentation and management of nervous system cavernous malformations in children: A systematic review and case report.

Authors:  Uma V Mahajan; Mohit Patel; Jonathan Pace; Brian D Rothstein
Journal:  Brain Circ       Date:  2022-09-21

4.  Natural history of incidentally diagnosed brainstem cavernous malformations in a prospective observational cohort.

Authors:  Jing-Jie Zheng; Pan-Pan Liu; Liang Wang; Li-Wei Zhang; Jun-Ting Zhang; Da Li; Zhen Wu; Yu-Mei Wu
Journal:  Neurosurg Rev       Date:  2020-05-12       Impact factor: 3.042

Review 5.  Pediatric cerebral cavernous malformations: Genetics, pathogenesis, and management.

Authors:  Michael G Z Ghali; Visish M Srinivasan; Arvind C Mohan; Jeremy Y Jones; Peter T Kan; Sandi Lam
Journal:  Surg Neurol Int       Date:  2016-12-28

Review 6.  Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel.

Authors:  Amy Akers; Rustam Al-Shahi Salman; Issam A Awad; Kristen Dahlem; Kelly Flemming; Blaine Hart; Helen Kim; Ignacio Jusue-Torres; Douglas Kondziolka; Cornelia Lee; Leslie Morrison; Daniele Rigamonti; Tania Rebeiz; Elisabeth Tournier-Lasserve; Darrel Waggoner; Kevin Whitehead
Journal:  Neurosurgery       Date:  2017-05-01       Impact factor: 4.654

7.  How can we optimize the long-term outcome in children with intracranial cavernous malformations? A single-center experience of 61 cases.

Authors:  Dorian Hirschmann; Thomas Czech; Karl Roessler; Paul Krachsberger; Shivam Paliwal; Olga Ciobanu-Caraus; Anna Cho; Andreas Peyrl; Martha Feucht; Josa Maria Frischer; Christian Dorfer
Journal:  Neurosurg Rev       Date:  2022-06-09       Impact factor: 2.800

Review 8.  Neurological outcomes of untreated brainstem cavernous malformations in a prospective observational cohort and literature review.

Authors:  Da Li; Jing-Jie Zheng; Jian-Cong Weng; Liang Wang; Zhen Wu; Pan-Pan Liu; Ze-Yu Wu; Li-Wei Zhang; Jun-Ting Zhang
Journal:  Stroke Vasc Neurol       Date:  2021-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.